Navigation Links
Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
Date:12/21/2007

BRISBANE, Australia, Dec. 21 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today provided an update on clinical trial enrollment associated with its phase 3 hepatocellular carcinoma (HCC, primary liver cancer) study. The study has begun initiating sites and is now open for patient recruitment, though a thorough examination of available surgical cases has not yet found any eligible patients who are able to be enrolled by 31 December 2007. Consequently, the Company now anticipates that first patient in will be achieved early in the new year. Given the delay is solely due to the first site being initiated so close to year-end, the Company does not expect that this will have any impact on overall study timelines or registration strategy.

At this point in time, Progen has received regulatory approval to conduct the phase 3 trial in several countries. The Company has also obtained ethics approval at five trial centres, one of which has been initiated and is open to recruitment. Further regulatory and ethics approvals will follow early in 2008, and sites will be initiated as soon as they are able to begin enrollment.

About PI-88: PI-88 is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. In April 2007, data from a randomized phase II trial in the post resection liver cancer setting was presented at the European Association for the Study of the Liver (EASL) meeting in Barcelona, Spain. PI-88, in this disease setting, has been granted Orphan Drug designation by the European Medicines Evaluation Agency (EMEA) and Fast Track designation by the United States Food and Drug Administr
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
3. Progen Announces PI-88 Phase 2 Lung Cancer Results
4. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
5. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
6. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
10. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
11. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Eisai Inc. announced today that regulatory applications ... , European Union and Japan ... eribulin, for the treatment of patients with inoperable soft ... advanced or metastatic disease. These regulatory ... Phase 3 clinical trial (Study 309), which met its ...
(Date:7/30/2015)... , July 30, 2015 ... new research report with market overview, trends, ... forecast, porter analysis, recent developments, competitive scenario ... Global Industry Insight: Biosensors Market Development and ... (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) Explore ...
(Date:7/30/2015)... July 30, 2015   Gaumard® Scientific Company ... UNI®, the world,s first operating system to support ... available exclusively to Gaumard users. UNI® version 2.27.21.0 ... Newborn Tory™ S2200, as well as improvements to ... clinical measures such as EtCO 2 .  ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3
(Date:7/31/2015)... ... July 31, 2015 , ... Nutritional ... variety of nutritional and wellness products, announced the addition of Vincent Aquilino to ... therapy, active isolated stretching and the prevention and rehabilitation of injuries, has spent ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions ... recent implementation of Microsoft Dynamics GP for a senior living facility in Maine. ... supporting senior living communities in 16 states. This further expansion was again a ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... the growing number of individuals who remain undiagnosed, treatment options for patients are ... away from traditional CPAP therapy due to its overall lack of comfort and ...
(Date:7/30/2015)... ... 31, 2015 , ... Reduce Human Error on the Drug ... and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice ... and device firms reduce manufacturing errors by 50 percent or more, will conduct ...
(Date:7/30/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... Obama’s call to action by asking community members to contribute to the College’s “My ... “Helping more of our young people stay on track. Providing the support they need ...
Breaking Medicine News(10 mins):Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3
... transmission did not cause infection among caregivers in study ... study estimates that more than 12 percent of people ... infected with MRSA, or methicillin-resistant Staphylococcus aureus, and ... to others in their household. , The researchers, Dr. ...
... the cheerful, study finds , MONDAY, Aug. 10 (HealthDay News) ... more likely to develop heart trouble than those with a ... comes from the Women,s Health Initiative, which has tracked more ... , "In addition to looking at hormones and their effect ...
... , , WASHINGTON, Aug. 10 ... is an immigrant (legal or illegal) or the U.S.-born child (under ... one-fourth of those on Medicaid. While there has been some ... insurance plans, the enormous impact of immigration, both legal and illegal, ...
... , ROLLING HILLS ESTATES, Calif., ... Device Connectivity Conference & Exhibition, organized by The Center for ... at the Joseph B. Martin Conference Center at Harvard Medical ... an outstanding agenda with nationally recognized experts from academia, provider ...
... , , FLORENCE, Italy, Aug. 10 ... a North American subsidiary of its DEKA division. Based in San ... bringing a selected range of medical and aesthetic devices under the ... SmartXide DOT. , , The new management team ...
... , LAKEWOOD, N.J., Aug. 10 PLUS ... announced today that it has expanded its executive team with the addition ... M.D. to chief medical officer and Mark Machulcz to executive vice president ... Mr. Machulcz bring more than 30 years of combined anatomic pathology experience ...
Cached Medicine News:Health News:Staph Infection May Follow People Home From Hospital 2Health News:Optimism Good for Heart and Longevity 2Health News:Optimism Good for Heart and Longevity 3Health News:Inaugural Medical Device Connectivity Conference & Exhibition to Focus on Connecting Medical Devices to People, Workflow and Information Systems 2Health News:El.En. Group Establishes New Subsidiary, DEKA Medical, Inc. and Appoints Management Team 2Health News:PLUS Diagnostics Announces Senior Executive Appointments 2Health News:PLUS Diagnostics Announces Senior Executive Appointments 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: